- Late breaker poster presentation will feature updated SVR results from the Phase 2 trial of ACH-3102, NS5A inhibitor, plus sofosbuvir for the eight-week treatment of genotype 1 HCV -
- Three preclinical posters on ACH-3422, uridine-analog nucleotide prodrug, to be presented –
NEW HAVEN, Conn., Oct. 8, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced four abstracts have been accepted for presentation at The Liver Meeting® 2014, the 65th Annual Meeting of The American Association for the Study of Liver Diseases (AASLD), in Boston, November 7 – 11.
A late breaker poster presentation will be made providing updated results, including SVR12, from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus (HCV) infection. This trial is currently dosing patients in a follow-on six-week treatment cohort.
Furthermore, three additional posters will be presented detailing the preclinical profile of ACH-3422, a uridine-analog nucleotide that continues to advance through its Phase 1 clinical development program.
David Apelian, M.D., Ph.D., Executive Vice Present and Chief Medical Officer, commented, "We are delighted that Achillion's ongoing research into HCV with ACH-3102 will be featured in a late breaker poster presentation during the 2014 Liver Meeting. Furthermore, as we work to complete the Phase 1 trial of ACH-3422, we are pleased to have the opportunity to present new preclinical research detailing the profile of ACH-3422."
Publication No. LB-23
Title: Interim sustained virologic response (SVR), safety and tolerability results of 8-week treatment with ACH-3102 and sofosbuvir in chronic hepatitis C (HCV), genotype-1 (GT-1), treatment-naïve patients: a Phase 2 "proxy" study
Authors: E. Gane, H. Kocinsky, C. Schwabe, et al.
Date/Time: Monday, November 10th, 8:00 a.m. - 5:30 p.m. ET.
Session: Late-Breaking Poster Session
Room: John B. Hynes Convention Center, Hall C
Publication No. 1978
Title: ACH-3422, a novel HCV NS5B RNA polymerase nucleotide inhibitor, demonstrates improved potency over sofosbuvir against HCV genotype-3 replicons in vitro
Authors: Y. Zhao, S. Podos, J. Fabrycki, et al.
Date/Time: Tuesday, November 11th, 8:00 a.m. – 12:00 p.m. ET.
Session: Hepatitis C: Preclinical Development Poster Session
Room: John B. Hynes Convention Center, Hall C
Publication No. 1982
Title: A novel approach to HCV resistance selection featuring short treatment duration and reduced interference from host cell adaptation
Authors: J. Fabrycki, Y. Zhao, D. Patel, et al.
Date/Time: Tuesday, November 11th, 8:00 a.m. – 12:00 p.m. ET.
Session: Hepatitis C: Preclinical Development Poster Session
Room: John B. Hynes Convention Center, Hall C
Publication No. 1985
Title: Antiviral activity and resistance emergence: combinations of the NS5B nucleotide inhibitor ACH-3422 with other antiviral agents in vitro
Authors: D. Patel, Y. Zhao, J. Fabrycki, et al.
Date/Time: Tuesday, November 11th, 8:00 a.m. – 12:00 p.m. ET.
Session: Hepatitis C: Preclinical Development Poster Session
Room: John B. Hynes Convention Center, Hall C
Additional information including the date and time of presentations are provided below. Reprints of the posters will be made available on the Company's website at www.achillion.com/resources and accessible after presentation at AASLD.
- Three preclinical posters on ACH-3422, uridine-analog nucleotide prodrug, to be presented –
NEW HAVEN, Conn., Oct. 8, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced four abstracts have been accepted for presentation at The Liver Meeting® 2014, the 65th Annual Meeting of The American Association for the Study of Liver Diseases (AASLD), in Boston, November 7 – 11.
A late breaker poster presentation will be made providing updated results, including SVR12, from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus (HCV) infection. This trial is currently dosing patients in a follow-on six-week treatment cohort.
Furthermore, three additional posters will be presented detailing the preclinical profile of ACH-3422, a uridine-analog nucleotide that continues to advance through its Phase 1 clinical development program.
David Apelian, M.D., Ph.D., Executive Vice Present and Chief Medical Officer, commented, "We are delighted that Achillion's ongoing research into HCV with ACH-3102 will be featured in a late breaker poster presentation during the 2014 Liver Meeting. Furthermore, as we work to complete the Phase 1 trial of ACH-3422, we are pleased to have the opportunity to present new preclinical research detailing the profile of ACH-3422."
Publication No. LB-23
Title: Interim sustained virologic response (SVR), safety and tolerability results of 8-week treatment with ACH-3102 and sofosbuvir in chronic hepatitis C (HCV), genotype-1 (GT-1), treatment-naïve patients: a Phase 2 "proxy" study
Authors: E. Gane, H. Kocinsky, C. Schwabe, et al.
Date/Time: Monday, November 10th, 8:00 a.m. - 5:30 p.m. ET.
Session: Late-Breaking Poster Session
Room: John B. Hynes Convention Center, Hall C
Publication No. 1978
Title: ACH-3422, a novel HCV NS5B RNA polymerase nucleotide inhibitor, demonstrates improved potency over sofosbuvir against HCV genotype-3 replicons in vitro
Authors: Y. Zhao, S. Podos, J. Fabrycki, et al.
Date/Time: Tuesday, November 11th, 8:00 a.m. – 12:00 p.m. ET.
Session: Hepatitis C: Preclinical Development Poster Session
Room: John B. Hynes Convention Center, Hall C
Publication No. 1982
Title: A novel approach to HCV resistance selection featuring short treatment duration and reduced interference from host cell adaptation
Authors: J. Fabrycki, Y. Zhao, D. Patel, et al.
Date/Time: Tuesday, November 11th, 8:00 a.m. – 12:00 p.m. ET.
Session: Hepatitis C: Preclinical Development Poster Session
Room: John B. Hynes Convention Center, Hall C
Publication No. 1985
Title: Antiviral activity and resistance emergence: combinations of the NS5B nucleotide inhibitor ACH-3422 with other antiviral agents in vitro
Authors: D. Patel, Y. Zhao, J. Fabrycki, et al.
Date/Time: Tuesday, November 11th, 8:00 a.m. – 12:00 p.m. ET.
Session: Hepatitis C: Preclinical Development Poster Session
Room: John B. Hynes Convention Center, Hall C
Additional information including the date and time of presentations are provided below. Reprints of the posters will be made available on the Company's website at www.achillion.com/resources and accessible after presentation at AASLD.
No comments:
Post a Comment